FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

KARSEN PERRY A 		2. Issuer Name and Ticker or Trading Symbol

CELGENE CORP /DE/ [ CELG ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
see remarks
(Last)          (First)          (Middle)

C/O CELGENE CORPORATION, 86 MORRIS AVENUE 		3. Date of Earliest Transaction (MM/DD/YYYY)

5/13/2015
(Street)

SUMMIT, NJ 07901
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   5/13/2015     M    6160   A $36.90   85683   D    
Common Stock   5/13/2015     M    11824   A $59.235   97507   D    
Common Stock   5/13/2015     M    8324   A $49.475   105831   D    
Common Stock   5/13/2015     M    4162   A $36.465   109993   D    
Common Stock   5/13/2013     S    47173   D $115.00   (1) 62820   D    
Common Stock                  2000   I   IRA Account  
Common Stock                  1639   I   401(k) Plan  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   $36.96   5/13/2015     M         6160      (2) 3/1/2022   Common Stock   6160   $0.00   (3) 0   D    
Stock Option (right to buy)   $59.235   5/13/2015     M         11824      (2) 4/29/2023   Common Stock   11824   $0.00   (3) 5912   D    
Stock Option (right to buy)   $49.475   5/13/2015     M         8324      (2) 1/28/2023   Common Stock   8324   $0.00   (3) 4162   D    
Stock Option (right to buy)   $36.465   5/13/2015     M         4162      (2) 4/30/2022   Common Stock   4162   $0.00   (3) 0   D    

Explanation of Responses:
( 1)  These shares were sold by the reporting person pursuant to a Rule 10b5-1 plan.
( 2)  The option was fully exercisable.
( 3)  The option was issued pursuant to the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 17, 2013).

Remarks:
Chief Executive Officer of Celgene Cellular Therapuetics

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
KARSEN PERRY A
C/O CELGENE CORPORATION
86 MORRIS AVENUE
SUMMIT, NJ 07901

see remarks

Signatures
/s/ Robert J. Hugin _____________________ Robert J. Hugin, Attorney-in-Fact 5/15/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Celgene Charts.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Celgene Charts.